Bionano Genomics Enters Into Debt and Equity Financing Agreements Totaling $41.5 Million in Commitments

SAN DIEGO–(BUSINESS WIRE)–Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today announced it has entered into financing agreements totaling $41.5 million in debt and equity commitments from affiliates of Innovatus Capital Partners, LLC, East West Bank and Aspire Capital Fund, LLC. Below is a summary of the foregoing agreements: T

Click to view original post